Tertomotide Withdrawn Phase 2 Trials for Moderate Alzheimer's Disease Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03959553GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)